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ABSTRACT
On October 25 and 26, 2007, at the University of
Toronto, the Gairdner Foundation in partnership with
Canadian Institutes of Health Research presented a
two-day international symposium titled Minds That
Matter. The symposium featured academic lectures
by Gairdner Award winners past and present and by
other leading biomedical scientists. These distin-
guished researchers share many characteristics in
common: creativity, vision, tenacity, and driving cu-
riosity to illuminate discovery with high degree of
relevance. The present article summarizes the 2007
Gairdner Award lectures.
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1. INTRODUCTION
The year 2007 marked the 48th presentation of the
prestigious Gairdner Awards. Among the 288 past
recipients of these awards, 70 individuals went on to
win a Nobel Prize. Two of those Nobel Laureates
presented at the 2007 symposium, Minds That Mat-
ter. All of the 2007 Gairdner Award lectures were
given at the MacLeod Auditorium, Medical Sciences
Building, on the University of Toronto campus in
downtown Toronto. In the true spirit of the academic
community, attendance was open to anyone and was
free of charge.
2. THE LECTURES
Welcoming remarks by Dr. John Dirks, President of
the Gairdner Foundation and chair of the morning
session, and by Dr. Catharine Whiteside, Dean, Fac-
ulty of Medicine, University of Toronto, launched
Day 1 of the symposium.
2.1 Day 1, Morning
Dr. C. David Allis, Gairdner Laureate 2007 and Joy
& Jack Fishman Professor, The Rockefeller Univer-
sity, New York, New York, kicked off the scientific
lectures with “Beyond the double helix: reading and
writing the ‘histone code’.” Allis proposed the “his-
tone code hypothesis,” a universal mechanism for
modifications in histone proteins that affect the sta-
bility of the genome and gene transcription. Moving
beyond the major assumption in biomedicine that
genes determine disease, Allis turned to epigenetics,
the inheritance of phenotype differences not based
on changes in DNA sequence, by asking if more could
be at play than just a genetic blueprint. The answers
came from his work on posttranslational modifica-
tions of histones, linking histones to cancer by dem-
onstrating that “cancer-related proteins ‘write and
read’ histone methyl marks,” thus balancing gene
expression. This knowledge changes the scientific
understanding of the Watson–Crick double helix by
demonstrating that the posttranslational modification
of histones has cancer implications—a mechanism
that points beyond humanity’s genetic blueprint. To
date, several “drug-able” targets aiming at the
epigenome have been identified. Applying knowl-
edge of cancer epigenetics, researchers are design-
ing new targeted therapies that halt the gene
regulation by posttranslationally modified histones
that can ultimately result in aberrant cell growth and
differentiation leading to cancer.
Continuing with the genome theme, Dr. Kim
Nasmyth, Gairdner Laureate 2007 and Whitley Pro-
fessor of Biochemistry, University of Oxford, Ox-
ford, U.K., presented a series of his discoveries
relating to mechanisms in cell division in “Protein
rings that bind DNAs together—a new principle of
chromosome organization essential for life?” Sister
chromatid cohesion is essential for mitosis, resulting
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in a “tug of war,” because the chromatids do not eas-
ily separate. Nasmyth examined the mechanism by
which a cell ensures that sister chromatids move to
opposite sides of the cell by asking what holds the
chromatids together and what triggers the destruc-
tion of that bond when they are ready to separate. He
demonstrated that the bond is created by a multi-sub-
unit protein complex called cohesin, a “molecular
glue” that holds chromosomes together. Cohesin, a
heterodimer, circularizes to form a gigantic ring struc-
ture that may hold sister chromatids together by em-
bracing them topographically. As the cohesin
dimerization domain twists open, it acts as a receptor
to bind DNA, and as the DNA enters via the cohesin
hinge, the cohesin ring shuts, trapping sister chro-
matids in its midst. Conversely, the carefully regu-
lated protein separase destroys sister chromatid
cohesion by cleaving one of the cohesin subunits.
This knowledge has therapeutic implications in can-
cer treatment, because drug targets can now be de-
signed to prevent opening of the cohesin ring, thus
inhibiting aberrant cell division and proliferation.
Similar applications are possible for other diseases,
such as a severe form of the developmental defect
Cornelia de Lange syndrome, caused by a mutation
in the cohesin protein (Smc), demonstrating that
cohesin’s role goes beyond mitotic function.
Shifting focus from the genome, Dr. Harry
Noller, Gairdner Laureate 2007 and Professor of
Molecular Biology, University of California, Santa
Cruz, California, offered a glimpse of ribosomes in
action using biophysical methods in “Ribosome
structure and dynamics: caught in the act.” Refer-
ring to the ribosome as a “molecular machine,”
Noller described structural dynamics of the ribosome
during transcriptional movement (translocation) of
tRNA through the ribosome. Using fluorescence reso-
nance energy transfer analysis, he directly observed
the intersubunit movement inside a single ribosome
by detecting changes in fluorescence. This mechani-
cal “ratcheting” (rotating) movement between two
ribosomal subunits facilitated the movement of tRNA
along the ribosome during protein synthesis. Ribo-
somes fluctuate spontaneously between the classical
and hybrid states in the absence of elongation factor
(which promotes the activity of guanosine triphos-
phate), and thermal energy is sufficient to account
for the intersubunit rotation underlying the mecha-
nism of translocation. Translation occurs as a series
of translation-and-pause events, dwell times fall into
the range 0.5–5 s, and translocation events measure
three bases and take place in less than 0.1 s. Better
understanding of the translocation of tRNA through
the ribosome can lead to strategies for the design of
novel antibiotics against pathogenic bacteria that have
evolved a variety of mechanisms of resistance to al-
most all commonly used antibiotics, leading to a
worldwide resurgence in serious illness caused by
bacterial infections.
Dr. Noller’s lecture on the structure of ribosome
set the stage for “From the structure of the ribosome
to the design of drugs” by Dr. Thomas A. Steitz,
Gairdner Laureate 2007 and Sterling Professor of
Chemistry, Yale University, New Haven, Connecti-
cut. Knowledge of the structure of the ribosome can
be used to design drugs against antibiotic-resistant
bacteria (whose “evolution trumps intelligent design,”
added Steitz). In his studies, Steitz examined bind-
ing of antibiotics to the 50S ribosomal subunit and
the mechanisms of resistance. His pioneering work
on the structure and function of the large ribosomal
subunit demonstrated that bacterial protein synthesis
involves an RNA-catalyzed reaction step, and he iden-
tified a structural basis for targeting the ribosome,
laying the foundation for the development of novel
antibiotics effective against resistant bacteria. Ribo-
somes contain many closely spaced sites to which
antibiotics can bind, and a “combo-antibiotic” that
can bind to various ribosomal sites can potentially
be designed, becoming a force in overcoming antibi-
otic resistance.
2.2 Day 1, Afternoon
The focus of the afternoon session, chaired by Dr. Jim
Woodgett, Senior Investigator, Director of Research,
Samuel Lunenfeld Research Institute, Toronto, On-
tario, changed from progress in molecular and cellu-
lar biology to advances in the treatment of cancer.
Dr. Dennis Slamon, Gairdner Laureate 2007 and
Chief, Division of Hematology/Oncology, David
Geffen School of Medicine at the University of Cali-
fornia–Los Angeles, Los Angeles, California, opened
the session with “Molecular diversity of human breast
cancer: biologic and therapeutic implications.” Rec-
ognizing that breast cancer is highly heterogeneous,
Slamon’s groundbreaking work led to the design of
trastuzumab (Herceptin: Genentech, San Francisco,
CA, U.S.A.) to treat breast cancer in patients over-
expressing HER2 receptor and revolutionizing how
breast cancer is characterized and treated. As a re-
sult, clinicians can pre-select patients with this alter-
ation and treat them with targeted therapy, producing
remarkable results. In the anthracycline-based adju-
vant setting, treating patients who have HER2-posi-
tive tumours with trastuzumab improved disease-free
and overall survival, but increased cardiotoxicity. In
an attempt to eliminate anthracyclines from treatment
regimens, new studies focusing on targeted biologic
therapies are underway.
Based on the hypothesis that upregulation of vas-
cular endothelial growth factor (VEGF) in HER2-posi-
tive metastatic breast cancer contributes to the
aggressive phenotype of this disease subgroup, the
“angiogenic switch” modulated by trastuzumab can
be exploited in the clinic by combined blockade of
these two “linked” pathways. Based on the knowl-
edge that neoangiogenesis is increased in HER2-posi-KRASNOSHTEIN and NIKOLOV
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tive tumours, a new targeted therapy that combines
two biologics, trastuzumab and the anti-VEGF antibody
bevacizumab (Avastin: Genentech), was tested in the
absence of anthracyclines in first-line metastatic
breast cancer. In phase I and II clinical trials, this drug
combination demonstrated no untoward toxicity and
resulted in a 53% overall response rate and an 86%
clinical benefit, setting the stage for phase III trial.
Using specificity of this kind, other cancers could
possibly be identified and treated in similar ways. As
the genetic information that drives tumours is identi-
fied, better outcomes are predicted with less cyto-
toxic therapies.
A pioneer in work on chromosome translocation,
Dr. Janet Rowley, Gairdner Laureate 1996 and Blum–
Riese Distinguished Service Professor of Medicine,
Molecular Genetics and Cell Biology and Human
Genetics, University of Chicago, Chicago, Illinois,
presented “Gene expression in acute myeloid leuke-
mia.” Focusing on chromosome abnormalities in can-
cer, Rowley discussed how aberrant karyotypes lead
to malignancies and how understanding the molecu-
lar changes in tumours can lead to more success in
treating them. Rowley discovered the Philadelphia
chromosome, the first recognized chromosomal ab-
normality caused by a translocation between the long
arms of chromosomes 9 and 22, t(9;22), and resulting
in chronic myeloid leukemia (CML). Today, several
chromosome translocations have been identified in
acute myeloid leukemia (AML), and breakpoints have
been cloned. Rowley described the current model of
the microRNA (miR) mechanism, and how miR analy-
sis can be used as a diagnostic tool to track transloca-
tions in AML samples. Differential expression of four
miRs in AML as compared with acute lymphoblastic
leukemia allows for those two leukemias to be distin-
guished, diagnosed, and appropriately treated. Future
challenges involve identifying additional genetic
changes that collaborate with each translocation and
developing a more effective therapy targeted to the
genes involved in each translocation and to the col-
laborators. Instead of studying one gene or pathway
at a time, which may give a distorted and incomplete
view of the cell, a more comprehensive approach that
simultaneously analyzes multiple genes and pathways
is required.
Continuing with the theme of leukemias started
by Rowley, Dr. Brian Druker, Howard Hughes Medi-
cal Institute, Professor of Medicine, Oregon Health
and Science University, Portland, Oregon, focused on
“Imatinib (Gleevec) as a paradigm of targeted cancer
therapies”—an example of how structural analysis of
protein can guide drug research. In a Philadelphia
chromosome, the t(9;22) translocation brings together
two genes: the BCR (breakpoint cluster region) gene
on chromosome 22 and the proto-oncogene ABL
(Ableson leukemia virus) on chromosome 9, result-
ing in a hybrid gene BCR-ABL that codes for a fusion
protein with tyrosine kinase activity, which activates
signal transduction pathways, leading to uncontrolled
cell proliferation. In CML, BCR-ABL was used as a
therapeutic target, resulting in development of imatinib
mesylate (Gleevec: Novartis Pharmaceuticals,
St. Louis, MO, U.S.A.). Imatinib is currently stan-
dard therapy in CML, but despite its success, some pa-
tients relapse because of mutations in ABL, a
circumstance that has led to the development of the
novel ABL inhibitors nilotinib (AMN107) and
dasatinib (Sprycel: Bristol–Myers Squibb, Princeton,
NJ, U.S.A.), which are more potent than imatinib.
Druker noted that one of the most important lessons
learned from his research is that “it’s all about the
target!” Early treatment of disease by identifying the
right target and matching the right patient to the right
drug can have a positive effect on the patient’s dis-
ease-free survival and overall survival after a diagno-
sis of cancer.
Continuing with targeted therapy, Dr. Napoleone
Ferrara, Genetech Fellow, Staff Scientist, San Fran-
cisco, California, presented “Anti-angiogenic therapy
for cancer and other disorders.” Ferrara described a
series of experiments in which inhibition of VEGF-
mediated angiogenesis resulted in suppression of tu-
mour growth in vivo, which led to the development
of the recombinant humanized monoclonal anti-VEGF
antibody bevacizumab. Bevacizumab was the first
biologic that demonstrated survival advantage in pa-
tients with various tumours that did not respond to
standard therapy. In the BRiTE (Bevacizumab Regi-
men—Investigation of Treatment Effect) trial, the
addition of bevacizumab to a variety of chemotherapy
regimens improved progression-free survival in meta-
static colorectal cancer with overall survival of 91%
at 6 months and 77% at 12 months. Angiogenesis also
contributes to the pathologic state in age-related
macular degeneration, in which blood vessel growth
leads to development of lesions. Ranibizumab injec-
tion (Lucentis: Genentech) was developed for the
treatment of neovascular age-related macular degen-
eration and was approved by the U.S. Food and Drug
Administration (FDA) in 2006 based on data from two
large, pivotal phase III clinical trials in which patients
demonstrated improvement in visual acuity and re-
mained stable after two years of treatment.
Targeting VEGF appears to result in clinical ben-
efit beyond cancer. Other studies have demonstrated
that bone marrow cells participate in the regulation
of tumour angiogenesis, and tumours less respon-
sive to anti-VEGF-A monotherapy recruit more bone
marrow cells, suggesting that the tumour primes the
bone marrow and instructs it to become angiogenic.
Elucidating alternative angiogenic mechanisms may
therefore broaden the therapeutic targets for treat-
ment of cancers and other diseases. In physiologic
angiogenesis, VEGF is a key regulator, and targeting
VEGF is now a validated strategy for the treatment of
several malignancies. Optimizing duration of treat-
ment and combinations with other inhibitors of2007 GAIRDNER INTERNATIONAL AWARDS LECTURES
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angiogenesis may enhance the clinical effectiveness
of VEGF inhibitors.
In “HPV vaccines and the prevention of genital
cancers,” Dr. Douglas R. Lowy, Laboratory of Cel-
lular Oncology, Division of Basic Sciences, National
Cancer Institute, National Institutes of Health,
Bethesda, Maryland, presented an overview of human
papillomavirus (HPV)–induced disease, with cervical
cancer being second to breast cancer as the most com-
mon cancer in women worldwide. Nearly all cases
of cervical cancer (20% in women worldwide, and
80% in the developing world) and other mucosal,
cutaneous, and oral cancers stem from HPV infection.
Designed by choosing an appropriate molecular tar-
get (L1 capsid protein), two distinct HPVL1 vaccines
are now being marketed:
• Gardasil (Merck and Co., Whitehouse Station,
NJ, U.S.A.), approved in 2006 in Canada and the
United States (women aged 9–26 years) and in
the European Union (women aged 9–26 years and
boys aged 9–15 years); and
• Cervarix (GlaxoSmithKline, Philadelphia, PA,
U.S.A.), approved in 2007 in the European Union
(women aged 10–25 years) and filed with U.S.
FDA in March 2007.
Although the vaccine is not a treatment or cure
for cervical cancer, it has demonstrated efficacy in
preventing infection by specific types of HPV if ad-
ministered to girls before the start of sexual activity.
Outstanding medical issues remain: Will the vaccine
continue to have an excellent safety and efficacy pro-
file after it has been given to thousands of people?
How long will the vaccine remain protective? Will
booster vaccinations be needed? Will the vaccine be
effective in boys and men? And might the eradicated
HPV types be replaced by other HPV types?
The current HPVL1 vaccines can reduce the in-
cidence of benign and malignant genital HPV infec-
tions, but their type-restricted protection means that
some serious infections will still occur in vaccinated
women. And it is unclear when the HPV vaccine will
be widely implemented in the developing world,
where most cases of cervical cancer occur. The need
for second-generation vaccines is widely recognized.
2.3 Day 2, Morning
The morning session of Day 2 of the symposium drew
a capacity crowd, welcomed by Dr. John Dirks, Presi-
dent, The Gairdner Foundation, and Dr. Phil Branton,
Director, Cancer Institute, Canadian Institutes of
Health Research, Ottawa, Ontario. “Advances in our
understanding of cancer” promised to be the under-
lying theme of the day.
From his work on a small nematode, Dr. Robert
Horvitz, Gairdner Laureate 1999, Nobel Laureate
2002, and Professor of Biology and Investigator,
Howard Hughes Medical Institute, Cambridge, Mas-
sachusetts, showed how misregulation of pro-
grammed cell death (apoptosis), a process that occurs
during normal development, can contribute to human
disease, particularly cancer. Too much cell death can
lead to neurodegenerative disease, cerebral stroke,
traumatic brain injury, AIDS, myocardial infarction,
congestive heart failure, acute liver injury, aplastic
anemia, and sepsis. However, too little cell death can
lead to cancer, autoimmune disease, and viral infec-
tions. In “Genetic control of programmed cell death
in [Caenorhabditis] elegans”, Horvitz provided an
overview of the core molecular genetic pathway of
apoptosis. According to Horvitz, programmed cell
death involves four major steps:
1. Identify the victim.
2. Kill.
3. Get rid of the corpse.
4. Destroy the evidence.
Because programmed cell death requires the func-
tion of specific genes, it is an active, biologic pro-
cess; and because Ced3 and Ced4 act within cells
that are going to die, programmed cell death is to at
least some extent a process of cellular suicide. The
C. elegans Ced3 looks like interleukin-1b–convert-
ing enzyme, a protease implicated in human inflam-
matory disease, and it can cause mammalian cells to
undergo apoptosis. Human Apaf1, which promotes
apoptosis in a cell-free system, is similar to Ced4.
Although CED3 (whose protein product acts like a
caspase) and CED4 are “killer” genes, CED9 is an
anti–cell death gene that looks like BCL2, a human
cancer gene that causes follicular lymphoma. And
because human Bcl2 can substitute for nematode
Ced9 in C. elegans, Ced9 and Bcl2 must act in mo-
lecular genetic pathways that are the same or similar.
Because caspases kill, caspase inhibition could pro-
tect against apoptosis in the treatment of disease with
too much cell death. Conversely, because the Ced9
and Bcl2 proteins are protective, their inhibition could
promote apoptosis in the treatment of diseases with
too little cell death. Knowing the genetic pathways
and the genes and proteins involved in apoptosis can
lead to the identification of therapeutic targets for
specific new drugs for cancer and other diseases.
Examining the “Mechanisms of metastatic
spread,” Dr. Robert Weinberg, Gairdner Laureate
1992 and Professor of Biology and Member, White-
head Institute, MIT, Cambridge, Massachusetts, dem-
onstrated that, during the normal differentiation
process, cell origin determines metastatic potential.
Whether a tumour arises and metastasizes is deter-
mined by a subset of cells called “tumour-initiating
cells” or “cancer stem cells.” A self-renewing stem
cell has the capability to seed a new tumour, but when
it enters a differentiation pathway, becoming a “tran-
sit amplifying” cell, it loses its tumour-inducing ca-KRASNOSHTEIN and NIKOLOV
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pability. Studies have demonstrated that successful
colonization is likely to depend on the self-renewal
capacity of disseminated micrometastatic cells and
their adaptation to novel microenvironments. To show
how cancer cells acquire those capabilities, Weinberg
described a series of experiments that demonstrated
the “metastatic education” of breast cancer cells (BCCs)
by signals released from mesenchymal stem cells re-
cruited to tumour-associated stroma. The BCCs used
an unknown signal to stimulate the recruited mesen-
chymal stem cells, which responded by releasing lym-
phoid tissue chemokine, CCL5, to which the BCCs
responded with increased motility and invasiveness.
Said Weinberg, “The nature of the cell-of-origin is a
strong determinant of the phenotype of the tumori-
genic cell, including its eventual tendency to metas-
tasize,” emphasizing that cell origin is important, and
a pre-existing normal differentiation of cell origin
determines metastatic phenotype.
In “Cancer stem cells,” Dr. John Dick, Profes-
sor, Medical Genetics and Microbiology, and Senior
Scientist, Division of Cellular and Molecular Biol-
ogy, Toronto General Research Institute, Toronto,
Ontario, discussed how an understanding of stem cells
in the leukemic process can be harnessed for thera-
peutic purposes. By asking which cell in cancer has
the capability to allow cancer to continue to prolifer-
ate, and using in vivo repopulation assay in nonobese
diabetic / severe combined immunodeficient mice,
Dick identified a small subset of stem cells that can
initiate leukemia. In AML, only leukemic stem cells
can initiate the disease, and little understanding has
been attained regarding how normal cells become
transformed in the initiation of leukemia. Using the
severe combined immunodeficient mouse model to
study functional heterogeneity in the hematopoietic
system, to characterize the developmental pathways
of both cell types, and to understand how the types
differ can lead to the elucidation of the mechanism
by which the leukemic process alters the develop-
ment of the normal blood system. A cancer stem cell
hierarchy model demonstrated functional heteroge-
neity within tumours, identifying a subset of self-re-
newing cells from bulk cancer that are responsible
for initiating and maintaining the disease clone. This
model has been demonstrated in a variety of cancers,
including breast (in 2003), brain (2004), colon (2006),
and AML (1994). These findings have therapeutic im-
plications: the elimination of the bulk tumour popu-
lation may not eradicate cancer stem cells, because
those cells may be dormant and drug-resistant, may
use cancer-specific pathways differently, or may have
altered niche requirements and altered migratory
properties. Insights into how the normal and leuke-
mic blood systems differ in their molecular pathways
will permit development of effective anti-leukemia
therapies that target leukemic stem cells and disrupt
the molecular process that leads to leukemia, and of
ways to prevent the disease from arising.
Dr. Tak Mak, Gairdner Laureate 1989, Profes-
sor and Director, The Campbell Family Institute for
Breast Cancer, and Senior Scientist, Division of
Stem Cell and Developmental Biology, Advanced
Medical Discovery Institute/Ontario Cancer Insti-
tute, Toronto, Ontario, opened his philosophical talk
“Did the oncogene revolution set back clinical on-
cology?” by saying that, “in 1976, the oncogene
revolution started and it is still going on.” Oncogene
research was stalled for a time, and—given popular
belief that “what is not too obvious must not be
good”—oncogenes were forgotten. Yet, oncogenes
are important players in cancer because of their in-
duction of cell proliferation and apoptosis. Survival
signals (phosphoinositide-3–kinase, Bcl2, nuclear
factor kB) block oncogene-induced cell death, which
makes survival and death pathways ideal targets for
therapeutic interventions. Imatinib mesylate, an in-
hibitor of cell survival, is a good example. Drugs
that target the survival signals that block oncogene-
induced apoptosis can help in the treatment of some
cancers. Members of the Rho family are important
in metastasis, because they are involved in motility
and invasiveness. In certain cells, RhoA transforms
and enhances invasiveness, and overexpression of
RhoC increases angiogenic factors in breast cells
in vitro and stimulates melanoma cells to exit the
blood and colonize lungs. Furthermore, oncogenes
affect metabolism in a profound way by allowing
some cancers to proliferate in low glucose condi-
tions by deriving energy from fatty acids. Targeting
cell metabolism to starve cancer by aiming at the
genes involved in alternative energy sources may
have therapeutic implications as an anticancer strat-
egy and could be the dawn of a new era in cancer
treatment.
2.4 Day 2, Afternoon
The afternoon session of Day 2, chaired by Dr. Ben
Neel, Director, Developmental Biology, Ontario Can-
cer Institute, Toronto, Ontario, continued with the
established theme: advances in the understanding of
cancer.
Approaching cancer as a disease of the genome,
Dr. Tom Hudson, President and Scientific Director,
Ontario Institute of Cancer Research, Toronto, On-
tario, spoke on “Genome variation and cancer.” The
landscape of human genome variation suggests that,
although most genetic polymorphisms are neutral,
some affect phenotype and therefore development of
disease. Most of the common genetic variations are
shared across populations, and the common variants
of interest to geneticists are those that give rise to
human disease—that is, common variants equal com-
mon disease. However, the universe of common varia-
tion in the human genome is small, amounting to
15 million polymorphisms. Hudson described sev-
eral genome projects in which genome-wide searches2007 GAIRDNER INTERNATIONAL AWARDS LECTURES
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are used to map polymorphisms and to look for pre-
dictors of disease. The goal of the International
HapMap Project is to describe common patterns of
sequence variation (haplotypes) in the human ge-
nome. Genome-wide searches lead to the identifica-
tion of new disease targets, which in turn enable the
design of screening tools for the early identification
of risk factors for diseases (including cancers) and
guide the development of appropriate treatments.
Genome projects such as the Human Genome, the
HapMap, and the Cancer Genome (including Assess-
ment of Risk of Colorectal Tumours in Canada) en-
able research into the complex nature of disease. The
most important contribution of these large-scale
projects to science is the generation and transfer of
resources, databases, and technologies to the scien-
tific community.
The need for predictors of cancer recurrence led
Dr. Todd Golub, Director, Broad Cancer Program,
The Broad Institute, Cambridge, Massachusetts, to
develop a method of genomic profiling that permits
the genetic signature or genetic profile of a tumour
to be studied in formalin-fixed tissue. In “Gene ex-
pression in cancer,” Golub described three genomic
profiles:
• Expression profiles of hepatocellular carcinoma
• Functional genomic profiles of myelodysplasia
syndrome
• Drug profiles (“signature-based screening”), and
how the use of these profiles in diseases includ-
ing cancer might help in devising ways to iden-
tify compounds of clinical relevance
Examining patterns of recurrence in hepatocel-
lular carcinoma and identifying marker genes led to
mapping of a “survival signature” in the liver. This
signature revealed some marker genes [for example,
antiviral and inflammation-related genes (MX1, MX2,
IRFs, IFIs) and oxidative stress response genes] and
overexpressed gene sets (interferon targets,
interleukin-6 targets, nuclear factor kB targets) that
contribute to a poor prognosis signature, and other
marker genes (for example, CYPs, AKRs, serum pro-
teins) and overexpressed gene sets (for example, liver
metabolism) that confer a good prognosis signature.
Golub indicated that the signature database provides
a connectivity map between the physiologic language
of disease, the genetic language of genes, and the
organic chemistry language of drugs that can lead to
an identification of small molecules of interest with
therapeutic potential.
In “Breast cancer genetics and individual risk,”
Dr. Bruce Ponder, Professor of Oncology and Di-
rector of Cancer Research, U.K. Cambridge Research
Institute, Li Ka Shing Centre, Cambridge, U.K., dis-
cussed inherited predisposition in breast cancer and
the importance of finding genes that confer suscepti-
bility to cancer. Ponder said that looking at the distri-
bution of risk within a population and studying the
genes that accompany that distribution can yield in-
sights into the “genetic architecture” of common can-
cers, assisting with the design of interventions and
screening. Ponder described the use of small nucle-
otide polymorphisms (SNPs) as arbitrary markers in
genome scans to search for common genetic vari-
ants, leading to a correlation of SNPs with tumour
phenotype. Using SNPs closely linked with tumour
phenotypes and genome-wide scanning, candidate
gene results from the Breast Cancer Association Con-
sortium (comprising 21 groups worldwide) identi-
fied five top gene loci, including FGFR2 and
MAP3K1. Based on loci from candidate studies, ap-
proximately 5% of genetic variance could be ex-
plained, and the identified genes were mostly novel
for cancer susceptibility. Ponder concluded that
whole-genome association is successful and repro-
ducible in finding common predisposing genes and
can be used as a screening tool to uncover individu-
als at high risk for developing cancer.
Moving from small molecules to worldwide epi-
demiologic studies, the final lecture of the sympo-
sium, “Changing cancer mortality” by Dr. Richard
Peto, Gairdner Laureate 1992 and Professor of Medi-
cal Statistics and Epidemiology, University of Ox-
ford, Oxford, U.K., focused on cancer mortality
trends. By examining cancer mortality trends attrib-
uted and not attributed to tobacco, Peto concluded
that smoking matters more than screening, preven-
tion, and treatment in cancer control, although the
latter three factors are important in cancer mortality.
Among all risk factors, tobacco is the biggest—big-
ger than chronic infection and occupational and hor-
monal factors. Worldwide, cancer mortality trends
decline when smoking cessation is introduced. From
a 50-year prospective U.K. study examining tobacco
hazards and mortality trends attributable and not at-
tributable to tobacco, three main messages emerged
for the individual smoker:
• The risk is big: half of all smokers are killed by
their habit.
• A quarter are killed in middle age (35–69 years
old), losing many life-years.
• Stopping smoking works.
If current smoking patterns continue, world to-
bacco deaths are estimated to reach 1 billion at the
end of the 21st century as compared with 0.1 bil-
lion for the 20th century. Prevention of a substan-
tial proportion of the 450 million tobacco deaths
expected before the year 2050 requires adult smok-
ing cessation.
3. CONCLUSION
The two-day Minds That Matter academic sympo-
sium ended on a high note with closing remarks fromKRASNOSHTEIN and NIKOLOV
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Dr. John Dirks, who noted the completion of another
successful Gairdner International Awards lecture se-
ries by academic leaders in biomedical research
whose lifetime of dedication, curiosity, and drive have
culminated in unprecedented advances in the under-
standing and treatment of cancer.
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